Aspira Women's Health Inc.
AWHL- Exchange
- OTC
- Industry
- In Vitro & In Vivo Diagnostic Substances
- SEC CIK
- 0000926617
No open-market purchases or sales by Aspira Women's Health Inc. insiders were filed in the last 90 days; no institution reported holding it in 13F filings for Q2 2026; no superinvestor holds it.
Q2 2024 vs. Q1 2024
How the institutions holding Aspira Women's Health Inc. changed between Q1 2024 and Q2 2024.
All holders in Q2 2024All holders in Q1 2024
| Measure | Q1 2024 | Q2 2024 | Change |
|---|---|---|---|
| Holders | 23 | 26 | +3 |
| Shares | 1.89M | 1.40M | −496.7K (−26.2%) |
| Value | $6.15M | $2.08M | −$4.07M (−66.2%) |
New holders (5)
Institutions that held Aspira Women's Health Inc. at the end of Q2 2024 but not at the end of Q1 2024.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| The PNC Financial Services Group, Inc. | 15,000 | $22.4K | 0.00% |
| Two Sigma Securities, LLC | 13,492 | $20.1K | 0.00% |
| Citadel Advisors LLC | 11,754 | $17.5K | 0.00% |
| XTX Topco Ltd | 11,032 | $16.4K | 0.00% |
| HRT Financial LP | 10,903 | $16.0K | 0.00% |
Sold out (2)
Institutions that held Aspira Women's Health Inc. at the end of Q1 2024 and filed for Q2 2024 without it.
| Institution | Shares, Q1 2024 | Value, Q1 2024 |
|---|---|---|
| Fernwood Investment Management, LLC | 666 | $2.06K |
| Wells Fargo & Company | 51 | $158 |